Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression

Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting... and effective treatment for patients with ICCs and may Purpose: To evaluate the safety and oncologic efficacy of be particularly valuable in unresectable patients, or percutaneous thermal ablation of intrahepatic cholan- those who have already undergone hepatic surgery. giocarcinoma (ICC) and identify risk factors for local Tumor size and ablation modality were not associated tumor progression (LTP). with LTP, whereas primary tumors and superficially Materials and methods: Retrospective review of an located tumors were more likely to subsequently recur. institutional tumor ablation registry demonstrated that 20 patients (9 males, 11 females; mean age Key words: Cholangiocarcinoma—Microwave 62.5 ± 15.8 years) with 50 ICCs (mean size ablation—Radiofrequency ablation—CT 1.8 ± 1.3 cm) were treated with percutaneous radiofre- quency ablation (RFA) or microwave ablation (MWA) between 2006 and 2015. Thirty-eight of the treated ICCs Cholangiocarcinoma is the second most common pri- (76%) were metastases that developed after surgical mary liver malignancy, and intrahepatic cholangiocarci- resection of the primary tumor. Patient demographics, nomas (ICCs) account for approximately 5–10% of all procedure technical parameters, and clinical outcomes cholangiocarcinomas [1, 2]. These tumors are associated were reviewed. A Cox proportional hazards model was with high rates of morbidity and mortality because they used to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Abdominal Radiology Springer Journals

Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression

Loading next page...
 
/lp/springer_journal/thermal-ablation-of-intrahepatic-cholangiocarcinoma-safety-efficacy-Er7VxXoLkA

References (31)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Imaging / Radiology; Gastroenterology; Hepatology
ISSN
2366-004X
eISSN
2366-0058
DOI
10.1007/s00261-018-1656-3
Publisher site
See Article on Publisher Site

Abstract

and effective treatment for patients with ICCs and may Purpose: To evaluate the safety and oncologic efficacy of be particularly valuable in unresectable patients, or percutaneous thermal ablation of intrahepatic cholan- those who have already undergone hepatic surgery. giocarcinoma (ICC) and identify risk factors for local Tumor size and ablation modality were not associated tumor progression (LTP). with LTP, whereas primary tumors and superficially Materials and methods: Retrospective review of an located tumors were more likely to subsequently recur. institutional tumor ablation registry demonstrated that 20 patients (9 males, 11 females; mean age Key words: Cholangiocarcinoma—Microwave 62.5 ± 15.8 years) with 50 ICCs (mean size ablation—Radiofrequency ablation—CT 1.8 ± 1.3 cm) were treated with percutaneous radiofre- quency ablation (RFA) or microwave ablation (MWA) between 2006 and 2015. Thirty-eight of the treated ICCs Cholangiocarcinoma is the second most common pri- (76%) were metastases that developed after surgical mary liver malignancy, and intrahepatic cholangiocarci- resection of the primary tumor. Patient demographics, nomas (ICCs) account for approximately 5–10% of all procedure technical parameters, and clinical outcomes cholangiocarcinomas [1, 2]. These tumors are associated were reviewed. A Cox proportional hazards model was with high rates of morbidity and mortality because they used to

Journal

Abdominal RadiologySpringer Journals

Published: Jun 4, 2018

There are no references for this article.